These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8590244)

  • 1. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
    Henry DW; Marshall JL; Nazzaro D; Fox JL; Leff RD
    Am J Health Syst Pharm; 1995 Nov; 52(22):2570-3. PubMed ID: 8590244
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of ondansetron hydrochloride and five antineoplastic medications.
    Stewart JT; Warren FW; King DT; Fox JL
    Am J Health Syst Pharm; 1996 Jun; 53(11):1297-300. PubMed ID: 8725205
    [No Abstract]   [Full Text] [Related]  

  • 3. Stability of ondansetron and dexamethasone infusion upon refrigeration.
    Rolin C; Hecq JD; Vanbeckbergen DF; Jamart J; Galanti LM
    Ann Pharmacother; 2011 Jan; 45(1):130-1. PubMed ID: 21156815
    [No Abstract]   [Full Text] [Related]  

  • 4. Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium.
    Beran C; Howard MS; Baki G; Churchwell MD
    Int J Pharm Compd; 2024; 28(4):329-333. PubMed ID: 39094045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
    Stewart JT; Warren FW; King DT; Venkateshwaran TG; Ponder GW; Fox JL
    Am J Health Syst Pharm; 1997 Apr; 54(8):915-20. PubMed ID: 9114924
    [No Abstract]   [Full Text] [Related]  

  • 6. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days.
    Hagan RL; Mallett MS; Fox JL
    Am J Health Syst Pharm; 1996 Jun; 53(12):1431-5. PubMed ID: 8781690
    [No Abstract]   [Full Text] [Related]  

  • 7. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection.
    Evrard B; Ceccato A; Gaspard O; Delattre L; Delporte JP
    Am J Health Syst Pharm; 1997 May; 54(9):1065-8. PubMed ID: 9143656
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.
    Estan-Cerezo G; Jiménez-Pulido I; Rodríguez Lucena FJ; Matoses Chirivella C; Soriano-Irigaray L; Navarro-Ruiz A
    Farm Hosp; 2017 Sep; 41(5):625-629. PubMed ID: 28847252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
    Bougouin C; Thelcide C; Crespin-Maillard F; Maillard C; Kinowski JM; Favier M
    Am J Health Syst Pharm; 2005 Oct; 62(19):2001-5. PubMed ID: 16174836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture.
    Kirkham JC; Rutherford ET; Cunningham GN; Daneshmand KA; Falls AL
    Am J Health Syst Pharm; 1995 Jul; 52(14):1557-8. PubMed ID: 7552902
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical development of ondansetron injection.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
    Liaw CC; Wang CH; Chang HK; Kao CY; Huang JS
    Chang Gung Med J; 2000 Jul; 23(7):413-9. PubMed ID: 10974756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron: design and development of oral pharmaceutical suspensions.
    Gallardo Lara V; Gallardo ML; Morales Hernandez ME; Ruiz Martinez MA
    Pharmazie; 2009 Feb; 64(2):90-3. PubMed ID: 19320280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4 degrees C.
    Jhee SS; Jeong EW; Chin A; Inagaki K; Fox JL; Gill MA
    Am J Hosp Pharm; 1993 Sep; 50(9):1918-20. PubMed ID: 8135242
    [No Abstract]   [Full Text] [Related]  

  • 16. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride.
    Wu G; Powers D; Yeung S; Chen F; Neelon K
    Int J Pharm Compd; 2018; 22(1):86-94. PubMed ID: 29385389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis?
    Martin M
    J Clin Oncol; 1996 Apr; 14(4):1401-2. PubMed ID: 8648398
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.